A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

ClinicalTrials.gov ID: NCT07492680

Public ClinicalTrials.gov record NCT07492680. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion

Study identification

NCT ID: NCT07492680
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 260 participants

Conditions and interventions

Conditions

Solid Tumors

Interventions

BMS-986504 Drug
Carboplatin Drug
Daraxonrasib Drug
Gemcitabine Drug
Nab-paclitaxel Drug
Nivolumab + Relatlimab FDC Drug
Paclitaxel Drug
Pemetrexed Drug
Pumitamig Drug
Temozolomide Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 16, 2026
Primary completion: May 19, 2032
Completion: May 19, 2032
Last update posted: Mar 24, 2026

2026 – 2032

United States locations

U.S. sites: 18
U.S. states: 14
U.S. cities: 15

Facility	City	State	ZIP	Site status
Local Institution - 0096	San Francisco	California	94158	—
Local Institution - 0182	Aurora	Colorado	80045	—
Local Institution - 0122	Tampa	Florida	33612	—
Local Institution - 0178	Atlanta	Georgia	30322	—
Local Institution - 0106	Chicago	Illinois	60637	—
Local Institution - 0143	Baltimore	Maryland	21287	—
Local Institution - 0124	Boston	Massachusetts	02114	—
Local Institution - 0119	Ann Arbor	Michigan	48109-0922	—
Local Institution - 0129	Rochester	Minnesota	55905	—
Local Institution - 0174	Rochester	Minnesota	55905	—
Local Institution - 0181	Rochester	Minnesota	55905	—
Local Institution - 0142	Buffalo	New York	14263	—
Local Institution - 0170	New York	New York	10016	—
Local Institution - 0139	New York	New York	10021	—
Local Institution - 0100	Durham	North Carolina	27705	—
Local Institution - 0085	Houston	Texas	77030	—
Local Institution - 0086	Seattle	Washington	98109	—
Local Institution - 0134	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07492680, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 24, 2026 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07492680 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →